scholarly journals Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors

Author(s):  
Matthew B. Harrell ◽  
Kaylee Ho ◽  
Alexis E. Te ◽  
Steven A. Kaplan ◽  
Bilal Chughtai
2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Siri Drangsholt ◽  
Michelina Stoddard ◽  
Stephanie Sansone ◽  
Ahra Cho ◽  
Bilal Chughtai

2017 ◽  
Author(s):  
Tom Marjot ◽  
Nantia Othonos ◽  
Conor Woods ◽  
Jonathan Hazlehurst ◽  
Ahmad Moola ◽  
...  

2016 ◽  
Vol 87 (4) ◽  
pp. 312
Author(s):  
Furio Pirozzi Farina ◽  
Antonella Pischedda

Treatment-induced sexual dysfunctions (SD) are a recurrent and controversial topic in recent literature on the adverse events related to the use of 5-alpha-reductase inhibitors (5ARIs) (1, 2). In order to deal adequately with the various aspects of this topic, it is necessary to first cover some of the steps that allow a better definition and understanding of the subject.


2013 ◽  
Vol 154 (3) ◽  
pp. 83-92
Author(s):  
Mariann Harangi ◽  
Noémi Zsíros ◽  
Lilla Juhász ◽  
György Paragh

Statin therapy is considered to be safe and rarely associated with serious adverse events. However, a significant proportion of patients on statin therapy show some degree of intolerance which can lead to decreased adherence to statin therapy. The authors summarize the symptoms, signs and frequencies of the most common statin-induced adverse effects and their most important risk factors including some single nucleotide polymorphisms and gene mutations. Also, they review the available approaches to detect and manage the statin-intolerant patients. Orv. Hetil., 2013, 154, 83–92.


Sign in / Sign up

Export Citation Format

Share Document